The Suppression of MUC1 Expression in Cultured Cholangiocarcinoma Cells Using Antisense MUC1 Ribozyme Strategy

Authors

  • Valla Wamanutajinda Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Adisak Wongkajornsilp Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Yudhtana Sattawatthamrong Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Sukit Huabprasert Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University

Keywords:

-

Abstract

Ribozyme strategy has been employed to suppress the expression of target genes with a better efficacy than that of a regular antisense RNA strategy due to its favorable stoichiometry of the hybridization. A plasmid capable of controlling the expression of a portion of antisense RNA whose sequence is complementary to the 5' region of the coding sequence of MUC1 was constructed to include the requisite sequence of a hammerhead ribozyme. This plasmid is intended to suppress MUC1 expression. This novel plasmid was examined to see whether it functioned inside the harboring cell. Cultured cholangiocarcinoma cells prepared from the sediment of intrahepatic biliary fluid were employed as the transfection target since these cells have been confirmed to have high levels of MUC1 expression. The suppression of MUC1 expression in these cells after stimulation of the plasmid function for 16 h was demonstrated using flow cytometric analysis.

Downloads

Published

01-10-2002

How to Cite

Wamanutajinda, V. ., Wongkajornsilp, A. ., Sattawatthamrong, Y. ., & Huabprasert, . S. . (2002). The Suppression of MUC1 Expression in Cultured Cholangiocarcinoma Cells Using Antisense MUC1 Ribozyme Strategy. Siriraj Medical Journal, 54(10), 617–624. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/245318

Issue

Vol. 54 No. 10 (2002): October

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.